BMO Capital reiterated an Outperform rating and $36 price target on Pfizer (PFE), saying that 2025 guidance succeeds in meeting the majority of the firm’s expectations outlined in its preview, positioning the company for earnings per share expansion. The company’s guide only just missed the firm’s midpoint sales expectation, though midpoint EPS expectations of $2.90 in 2025 show roughly 2% growth year-over-year, giving investors confidence that the company has turned over a new leaf financially, the analyst tells investors in a research note. The firm continues to believe the revenue guidance is conservative, especially for ex-COVID products, leaving room for future beats and raises to sustain shares throughout the year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Barclays fact-checked Trump comments on pharmacy benefit managers
- Pfizer provides FY25 outlook, McCormick in talks for Sauer Brands: Morning Buzz
- Pfizer (NYSE:PFE) Surges as FY25 Forecast Aligns with Wall Street
- Early notable gainers among liquid option names on December 17th
- Morning Movers: Rockwell Medical jumps following product purchase agreement